What ChondroFiller injection is actually built to treat

Understanding where ChondroFiller injection is not appropriate starts with being precise about what it is designed to do — because the limits flow directly from the design.

ChondroFiller liquid is a CE-marked Class III injectable acellular Type I collagen scaffold, placed under ultrasound guidance in an outpatient setting. Its mechanism is acellular matrix-induced chondrogenesis: the collagen matrix acts as a recruiting structure for the patient's own progenitor cells, which migrate in and begin repair from within — no donor cells are delivered. The primary target is a focal Grade III or IV cartilage defect with healthy surrounding borders and a joint environment that can support that repair process.

The injectable form extends this envelope somewhat. Where the arthroscopic scaffold is built around a structurally contained focal lesion, the injection can also function as a top-down viscoelastic cushion over more diffuse wear — including Kellgren-Lawrence Grade III or IV osteoarthritis — where the goal shifts from structural repair to load absorption and symptom relief.

Those two roles together define the outer edges of candidacy. Defects that have destroyed the underlying bone require a different structural approach; joints with multi-compartmental bone-on-bone destruction sit beyond what a cushioning scaffold can meaningfully address. Every 'not suitable' scenario in this article traces back to one or both of those boundaries.

Hard contraindications — when the biology rules it out

Several factors disqualify a patient from ChondroFiller injection regardless of imaging findings or symptom severity. These are genuine clinical filters — not rare edge cases — and the pre-treatment assessment process exists precisely to identify them.

• Known allergy to murine-derived products or Type I collagen. ChondroFiller liquid is manufactured from murine-derived Type I collagen; this is intrinsic to the device. Patients with a confirmed allergy to murine or collagen products cannot safely receive it, and there is no equivalent non-collagen formulation as an alternative.
• Active joint infection. Introducing a collagen scaffold into an infected joint risks bacterial colonisation of the matrix and subsequent scaffold failure. The joint environment must be infection-free before any scaffold placement is appropriate.
• Inflammatory arthropathy — including rheumatoid and psoriatic arthritis. In these conditions, persistent synovial inflammation continues to attack joint tissue regardless of what is injected. The inflammatory environment degrades the scaffold before the patient's own progenitor cells can meaningfully colonise and differentiate within it, rendering the treatment ineffective.
• Absent or severely degraded surrounding cartilage borders. The scaffold integrates by anchoring to adjacent healthy cartilage. Where the surrounding tissue is itself too compromised to provide that foundation, successful integration is unlikely.
• Inability to follow post-injection activity guidance. Recovery from a collagen scaffold injection requires a period of managed loading. Patients who are unable — for any reason — to modify activity in the short term following treatment are unlikely to achieve the joint environment the scaffold needs to consolidate.

Malalignment — why a crooked knee undermines the injection

Mechanical alignment sits at the top of the structural candidacy assessment — above defect size, above OA grade, above almost every other factor — because no scaffold can compensate for a knee that is consistently overloading one compartment.

What malalignment means in practice. A varus knee, commonly described as bow-legged, angles the tibia inward relative to the femur, pushing the mechanical weight-bearing axis through the medial compartment. A valgus knee — knock-kneed — does the opposite, concentrating load on the lateral side. In either case, the affected compartment bears compressive and shear forces that a normally aligned knee distributes across a wider contact area.

Why this specifically undermines the scaffold. An injectable collagen scaffold relies on a stable, appropriately loaded joint environment during the weeks to months it takes for the patient's own progenitor cells to migrate in, differentiate, and begin consolidating repair tissue. When the compartment receiving that scaffold is simultaneously absorbing disproportionate mechanical stress, the newly forming tissue is placed under load it cannot yet tolerate. The result is scaffold disruption or failure before integration has occurred — not a marginal reduction in outcome, but a functional contraindication.

The corrective pathway. When varus malalignment is the dominant problem, high tibial osteotomy (HTO) realigns the weight-bearing axis away from the overloaded medial compartment and toward the lateral side. For valgus deformity, distal femoral osteotomy (DFO) performs the analogous correction for the lateral compartment. In patients where a focal cartilage defect coexists with correctable malalignment, osteotomy and cartilage repair may be staged or combined — but the alignment problem must be addressed first or simultaneously.

How malalignment is identified. Weight-bearing long-leg radiographs provide the definitive alignment assessment; Kellgren-Lawrence grading on weight-bearing X-ray runs alongside this to characterise OA severity in the affected compartment. Because there is no published angular threshold that uniformly disqualifies ChondroFiller candidacy, the decision is individualised at consultation, informed by the full radiographic and clinical picture.

End-stage OA — the point where injection cannot substitute for replacement

There is a ceiling to what any injectable scaffold — including ChondroFiller — can achieve, and it is important to name it clearly: when multi-compartmental bone-on-bone destruction is present, total knee replacement (TKR) is the clinically appropriate intervention, and no regenerative injection changes that calculus.

A viscoelastic collagen scaffold works by providing a matrix for the patient's own progenitor cells to colonise and consolidate repair tissue. Where the articular surfaces across multiple compartments have lost cartilage entirely, there is no remaining biological substrate for that process to work with, and the joint's structural demands exceed what any cushioning layer can address. In this setting, TKR is not a treatment failure — it is the right tool for the stage the disease has reached.

For disease confined to a single compartment, unicompartmental knee replacement (UKR) offers a more targeted surgical option that preserves the healthy compartments entirely.

In carefully selected patients — those with focal defects and Kellgren-Lawrence Grade III or early Grade IV changes in one compartment — ChondroFiller injection may delay the need for arthroplasty. But selection is the operative word: attempting injection at true end-stage disease does not remove the eventual need for replacement, and may defer it for the wrong reasons.

KL Grade IV in a single compartment is a genuine grey zone. Outcomes depend on the extent of bone-on-bone contact, the patient's activity level, and the overall joint environment — which is why this decision requires individualised assessment rather than a blanket rule.

What the alternatives look like when ChondroFiller is not appropriate

The right next step depends on the specific reason ChondroFiller was ruled out — matching the exclusion to the correct pathway is far more useful at this decision stage than a generic list of alternatives.

If malalignment is the primary barrier, osteotomy corrects the mechanical problem before cartilage work is considered: high tibial osteotomy (HTO) for varus knees, distal femoral osteotomy (DFO) for valgus. Both are operating-theatre procedures. Once the weight-bearing axis is corrected, a cartilage repair or injection approach may become viable — depending on what remains in the affected compartment.

If the defect is very small and self-contained (under 2 cm²), microfracture is an arthroscopic surgical option that stimulates the subchondral bone to produce a fibrocartilage fill. It is technically simpler than the alternatives, but the tissue it generates is fibrocartilage rather than hyaline-like cartilage, outcomes in published series often decline after 18–24 months, and reoperation rates reach up to 41%.

If the defect is larger (above 2–4 cm²) or involves bone loss beneath the cartilage layer, autologous chondrocyte implantation (ACI or MACI) produces hyaline-like repair tissue with IKDC improvements of approximately 30–35 points — though complication rates run as high as 17% and reoperation rates up to 37%. Where subchondral bone is significantly lost, osteochondral allograft transplantation becomes the appropriate choice. All three are operating-theatre procedures.

If an inflammatory arthropathy such as rheumatoid arthritis drove the exclusion, systemic disease-modifying anti-rheumatic drug (DMARD) therapy to control joint inflammation comes first; local cartilage intervention is not appropriate while active synovitis is present.

If end-stage multi-compartmental disease is the reason, unicompartmental knee replacement (UKR) for single-compartment destruction or total knee replacement (TKR) for multi-compartmental disease is the clinically appropriate pathway — as outlined in the preceding section.

How candidacy is assessed — and what a Lincolnshire Knee appointment involves

Reaching the end of this article with uncertainty is, in itself, a good reason to seek a structured assessment — because the questions raised here (alignment, OA grade, defect size, biology) are exactly what a candidacy review is designed to answer.

A Lincolnshire Knee assessment typically combines weight-bearing X-rays — read using Kellgren-Lawrence grading and alignment measurement — with MRI to characterise defect depth, size, and the quality of the surrounding cartilage. Where load distribution is a concern, onMRI™ AI-driven analysis supports detailed cartilage segmentation and T2 mapping without the need for surgery. MAI Motion® gait and biomechanical assessment can objectively identify how load is distributed across the knee — relevant where alignment appears borderline on static imaging alone.

The outcome of that assessment is not fixed in advance. It may be that ChondroFiller injection is appropriate. It may be that a different injection pathway better fits the clinical picture. It may be that a surgical opinion — for osteotomy, ligament reconstruction, or arthroplasty — is the logical next step. The assessment determines that; no article can.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without a GP referral, with no NHS-style waiting list. Book an assessment at lincolnshireknee.co.uk.